ViroPharma and Wyeth Commence Phase II Hepatitis Study
Posted on: Wednesday, 25 October 2006, 15:01 CDT
ViroPharma and Wyeth have commenced patient dosing in a phase II study of HCV-796, an inhibitor for the treatment of hepatitis C.
The objectives of this trial are to assess the safety, tolerability, pharmacokinetic profile and antiviral activity of HCV-796. The trial will asses HCV-796 when used in combination with pegylated interferon alfa-2b plus ribavirin compared to the current standard of care. The companies will add an additional dose or doses of HCV-796 to the trial to further elucidate the dose response.
"Following the strength of the phase I data, we have initiated a phase II program to assess the efficacy of the compound as part of a triple therapy combination, and to continue to add to our safety database," commented Stephen Villano, ViroPharma's vice president of clinical research and development.
Hepatitis C is a blood-borne virus recognized as a major cause of chronic hepatitis worldwide. The World Health Organization estimates that 170 million persons worldwide are infected with hepatitis C, and three to four million persons are newly infected globally each year.
Source: Datamonitor
Related Articles
- Idera Starts Phase I Trial for Hepatitis C Drug
- Idera Pharmaceuticals Initiates Phase 1 Trial of IMO-2125 in Hepatitis C
- Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
- FDA Grants Fast Track Status for HCV-796 for Treatment of Hepatitis C Virus Infection
- ViroPharma Announces Completion of Enrollment in 500mg BID Arms of HCV-796 Phase 2 Study
- ViroPharma and Wyeth Initiate Dosing in Phase 2 Study of HCV-796 in Treatment Naive Patients and Non-Responders
- ViroPharma Announces Positive Data From Phase 1b Combination Study of HCV-796 and Pegylated Interferon in Hepatitis C Patients
- ViroPharma Announces Presentation of HCV-796 Phase 1b Data at Digestive Disease Week
- ViroPharma Announces Presentation of Pharmacokinetic Data From HCV-796 Phase 1a Study
- ViroPharma Announces Start of HCV-796 Phase 1 Program
 |
 |
User Comments (0)
RSS Feeds